Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients-Reference-Cited by-同舟云学术

Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

Published:2021-11 Issue: Volume:73 Page:103626
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Carreño Juan Manuel^ORCID,Alshammary Hala,Singh Gagandeep,Raskin Ariel^ORCID,Amanat Fatima,Amoako Angela,Gonzalez-Reiche Ana Silvia^ORCID,van de Guchte Adriana^ORCID,study group PARIS,Srivastava Komal,Sordillo Emilia Mia^ORCID,Sather D. Noah,van Bakel Harm,Krammer Florian,Simon Viviana^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference52 articles.

1. SARS-CoV-2 vaccines in development;Krammer;Nature,2020

2. Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity;Denison;RNA Biol,2011

3. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus;Korber;Cell,2020

4. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity;Thomson;Cell,2021

5. Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020;Larsen;Euro Surveill,2021

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020–2023;Nature Communications;2024-07-11

2. Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays;Science Translational Medicine;2024-05-15

3. What makes SARS‐CoV‐2 unique? Focusing on the spike protein;Cell Biology International;2024-01-23

4. SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023;2023-12-18

5. Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial;2023-12-01